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 1 
Abstract 1 
The study of public perceptions is considered to be important for making sound policy 2 
decisions since the public decides which products will enter and sustain in the market. 3 
Stability of public perceptions is important for policy makers, only if public attitudes 4 
and perceptions remain constant policy-makers will be able to take them into account. 5 
The aim of the present study was to examine the stability of participants’ risk and benefit 6 
perceptions of gene technology over a period of two years. In spring, 2008 and in spring, 7 
2010, the same sample of participants filled out an identical questionnaire. Results of 8 
structural equation modelling show that risk and benefit perceptions of gene technology 9 
applications are moderately stable (r = 0.5 – 0.7). Furthermore, results show that people 10 
distinguish between medical, plant and food applications, and applications involving animals 11 
when evaluating the risk of gene technology. When evaluating the benefits, participants also 12 
take consumer-related benefits into account, such as enhancement of functional properties. 13 
Results of the present study suggest that risk research should regularly examine people’s risk 14 
perceptions in order to gain a clearer picture of the dynamics of people’s perception and 15 
preferences not only of novel technologies but also of entrenched technologies.  16 
Key words: Stability – Risk perception – Biotechnology – Longitudinal  17 
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Introduction 19 
There has been an increased interest in involving the public in decision-making 20 
processes about science and technology, especially with regard to issues concerning the 21 
management of environmental and health risks (Fife-Schaw and Rowe 2000; Horlick-Jones et 22 
al. 2006). Public involvement in policy matters is rooted in diverse reasons, but generally they 23 
are considered to derive from either a recognition of basic human rights regarding democracy 24 
and procedural justice (Perhac 1996) or simply from a practical point of view that 25 
implementing unpopular policies may result in widespread protest and reduced trust in 26 
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governing bodies (Kasperson, Golding, and Tuler 1992). However, the extent to which 27 
members of the public are interested and capable of being involved effectively in governance 28 
varies widely (Smiley, de Loe, and Kreutzwiser 2010). Since publics’ perception of risk can 29 
compel or constrain political, economical, or social action to address particular risks 30 
(Leiserowitz 2006) studying publics’ perceptions of risk over an extended period of time 31 
(e.g. a period of one to three years) is crucial for making sound policy decisions. However, 32 
there is a lack of studies that examined the stability of lay people’s technological risk 33 
perception over such an extended period of time. In furtherance to provide an insight of 34 
public perceptions of gene technology over an extended period of time the present study 35 
will investigate risk and benefit perceptions over a period of two years. Lay people’s 36 
perception of risks and benefits influences consumers’ behaviour and decision-making, the 37 
acceptance of the technology, and the willingness to buy novel products (Siegrist 2000). Only 38 
when public attitudes and perceptions relatively stable over time preferences pronounced by 39 
the public be taken into account by the government (Siegrist and Visschers 2012). There are 40 
few studies that examined the stability of people’s risk and benefit perceptions, however. To 41 
the best of your knowledge the stability of attitudes towards gene technology has not been 42 
examined, however. Gene technology is a modern tool of biotechnology providing the 43 
opportunity to overcome shortcomings of traditional breeding methods e.g. long 44 
selection processes. Gene technology can be seen as a continuously developing tool of 45 
biotechnology which itself is an entrenched technology.  46 
Longitudinal studies on technological risk perception 47 
The most important longitudinal studies on biotechnology perceptions are the studies 48 
conducted for the Eurobarometer. However, it should be noted that not that the 49 
Eurobarometer studies use a repeated cross-sectional study design meaning that not the 50 
same group of people had answered the questions in the different years. The first 51 
Eurobarometer study on biotechnology was conducted in 1991, followed by studies in 1993, 52 
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1996, 1999, 2002, 2005, and 2010. The Eurobarometer is based on a representative sample 53 
of 25,000 respondents, approximately 1000 in each EU member state. Results of the last 54 
Eurobarometer study in 2010 show that there are still deeply rooted views on GM food 55 
(Gaskell et al. 2010). The Eurobarometer studies provide a general overview about 56 
people’s perceptions of biotechnology, knowledge, and preferences and show that people’s 57 
perceptions change over time (Gaskell et al. 2010). Each Eurobarometer survey was further 58 
developed; more countries joined the European Union and further questions were added. The 59 
structure changed and the content evolved over the years and, therefore, it is rather difficult to 60 
directly compare the results over time. Due to the fact that a cross-sectional design was used 61 
in the Eurobarometer studies, it is impossible to assess the stability of individual’s 62 
responses over time. Acceptance or risk perception of nuclear power seems to be the 63 
only technology for which studies with a longitudinal panel design exist. 64 
Several studies have examined the impact of a nuclear accident on people’s perception 65 
and attitudes towards nuclear power utilizing a within subject design (Eiser, Spears, and 66 
Webley 1989; Verplanken 1989; Lindell and Perry 1990; Siegrist and Visschers 2012; 67 
Visschers and Siegrist 2013).  Participants’ attitude towards nuclear power was investigated 68 
before and after the Chernobyl accident in 1986 employing questionnaires (Eiser, Spears, and 69 
Webley 1989; Verplanken 1989; Lindell and Perry 1990) and a mixed method design of 70 
questionnaires and interviews (Verplanken 1989). These studies focused on mean changes of 71 
perceptions and attitudes towards nuclear power and not on associations between the two 72 
measurement times. Since there was a nuclear accident between the two measures that may 73 
have shaped people’s responses at the second and following measurement times no 74 
assessment in regard to the stability of people’s risk perceptions or acceptance of a technology 75 
can be made. 76 
Associations between two or more measurement points were investigated after the 77 
Fukushima disaster in 2011 (Siegrist and Visschers 2012; Siegrist, Sütterlin, and Keller 78 
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2014). Acceptance, perceived risks and benefits and trust related to nuclear power stations 79 
were assessed 5 months before and directly after the disaster employing a within subject 80 
design (Visschers and Siegrist 2013). Visschers & Siegrist (2013) show that the acceptance 81 
and perceptions as well as trust were more negative after the accident than before. However, 82 
perceived benefits before the accident correlated with perceived benefits after the accident (r 83 
= .52). Additionally, the relations of the determinants for people’s acceptance of nuclear 84 
power did not change after the accident indicating stability over time. Even after a severe 85 
accident, the public may still consider the benefits as relevant, and trust remains important for 86 
determining their risk and benefit perceptions (Visschers and Siegrist 2013). 87 
Mean changes and correlations between three measurement points were also 88 
investigated in relation to the Fukushima accident (Siegrist and Visschers 2012). Results of 89 
this survey research show that the accident had a negative impact on the acceptance of 90 
Nuclear power. However, high correlations were observed between all three measurement 91 
points and the mean changes were only moderate. Participants showed rather stable attitudes 92 
towards nuclear power (Siegrist and Visschers 2012). 93 
Perception of biotechnology applications 94 
There are many studies that have investigated people’s perceptions of biotechnology (see 95 
Lusk et al. (2005) and Frewer et. al (2013b) for a review). One of the main findings is that 96 
perceived risks and benefits are key factors in the acceptance of biotechnology (Frewer, 97 
Howard, and Shepherd 1997). In their review and meta-analysis Frewer and colleagues 98 
(2013) suggest that risk and benefit perceptions associated with all aspects of genetically 99 
modified agri-food application have been increasing over time. 100 
It has been shown that people have varying attitudes towards biotechnology applications 101 
in different fields (Connor and Siegrist 2013, 2010). Medical and non-medical applications 102 
are perceived differently; medical applications are perceived to be highly beneficial, and 103 
consumers see considerable value in the development of new medicines to combat disease 104 
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e.g. (Frewer, Howard, and Shepherd 1997; Connor and Siegrist 2010; Magnusson and Hursti 105 
Koivisto 2002). However, it has also been shown that people disapprove of the use of human 106 
genetic testing and may have moral objections towards the manipulation of human DNA 107 
(Pardo and Calvo 2008). Thus, people not only distinguish between different categories of 108 
applications, but also within the same category of application the perception varies (Frewer, 109 
Howard, and Shepherd 1997).  110 
Furthermore, Frewer et al. (1997) investigated people’s perceptions of biotechnology 111 
applications including genetically modified (GM) microorganisms, plants, human DNA, and 112 
animals. The results of this study show that applications involving microorganisms and plants 113 
were perceived to be beneficial, advantageous, and necessary, whereas applications involving 114 
human DNA and animals were perceived to be unethical, harmful, and dangerous (Frewer, 115 
Howard, and Shepherd 1997). Another distinction is made between first-generation GM crops 116 
and second-generation GM crops. First-generation GM crops are associated with producer-117 
related benefits like herbicide tolerance, insect resistance, and pathogen resistance. Although 118 
first-generation crop plants are seen to be useful, they are also perceived as risky and are not 119 
accepted (Gaskell 2000). Second-generation crop plants deliver consumer-related benefits, 120 
e.g. rapeseed with augmented functional properties. A study by Hartl and Herrmann (2009) 121 
investigated whether German consumers also rejected second-generation GM foods. Two 122 
different types of rapeseed, one that contains functional compounds such as long-chain 123 
omega-3 fatty acids and one that contains phytosterol, which translate into increased quality 124 
of oil derived from the crop, were investigated (Hartl and Herrmann 2009). Results of this 125 
study show that most participants were not interested in GM rapeseed oil. However, output 126 
traits such as enrichment of oilseed rape with omega-3 fatty acids increase the probability 127 
of the purchase of GM rapeseed oil (Hartl and Herrmann 2009). 128 
A number of studies showed that perceived benefits and perceived risks are the 129 
main factors influencing acceptance of gene technology (Siegrist 2000; Prati, 130 
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Pietrantoni, and Zani 2012; Tanaka 2013). Consumers who perceive tangible benefits 131 
associated with this technology are more likely to accept gene technology compared with 132 
consumers who do not associate benefits with this technology. Risk perception was also 133 
found to influence attitudes towards gene technology. Results of these studies suggest, 134 
however, that benefit perception is a stronger predictor for attitude or acceptance than 135 
perceived risks. 136 
Rationale of the present study 137 
Numerous studies about lay people’s risk perception have been published in recent 138 
years (Earle 2010; Frewer et al. 2011; Frewer et al. 2013b). With the exception of nuclear 139 
power, little is known how stable people’s risk perceptions are. Recent studies on attitudes 140 
about nuclear power showed stable attitudes (Siegrist and Visschers 2012) and stable 141 
determinants for people’s risk perception (Visschers and Siegrist 2013) even after a nuclear 142 
accident. It is unclear whether the results observed for nuclear power can be generalized 143 
to other technologies, however. It was the aim of the present study to investigate how stable 144 
perceptions of gene technology applications are. Gene technology is an entrenched 145 
technology for which people had a chance to develop stable attitudes. For technologies 146 
that are either well-known or well-established, we expect strong correlations for the risk 147 
perception, and the benefit perceptions, respectively. People may have acquired basic 148 
knowledge or have a fundamental underlying preference. Gene technology is a continuously 149 
developing technology, with newly emerging strains in the agricultural, food, and medical 150 
sectors. However, considering that gene technology is a tool of the well-entrenched 151 
technology biotechnology it is likely that people may have formed well-founded attitudes. 152 
The dimensions people use to make their evaluations of gene technology and its applications 153 
have been investigated at length throughout the last years; perceived risks and benefits are the 154 
important determinants (Frewer et al. 2013a) and will, therefore, serve as the subject matter 155 
for the present study. We do not expect great changes in people’s risk and benefit perceptions 156 
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of biotechnology applications due to the knowledge and familiarity people may have acquired 157 
over the past years. This would be also in line with research conducted on nuclear power 158 
(Eiser, Spears, and Webley 1989; Verplanken 1989; Lindell and Perry 1990; Visschers and 159 
Siegrist 2013; Siegrist and Visschers 2012). We, therefore, hypothesise that people’s risk and 160 
benefit perceptions of gene technology are stable over a period of two years. The aim was 161 
to examine whether perceptions related to gene technology are as stable as reported for 162 
nuclear power or whether for a technology that is perceived as less risky compared with 163 
nuclear power (Flynn, Slovic, and Mertz 1994) risk and benefit perceptions are less 164 
stable. 165 
Methods 166 
Participants 167 
Data for the present study come from two surveys conducted in spring, 2008 and in 168 
spring, 2010 in a German-speaking Swiss community (Reckenholz) where nearby field trials 169 
with GM wheat plants were carried out. The survey started when the first plants were visible. 170 
In 2008, people were asked to fill out a questionnaire, and additionally people were asked 171 
whether they would agree to fill out a questionnaire in two years’ time. The questionnaire 172 
was returned by 999 persons and the response rate was 42.5%. In 2010, these people 173 
received the exact same questionnaire, with two additional questions. The response rate was 174 
62.4%. Only participants for whom the data for gender and birthday were the same in both 175 
years and had complete data sets were considered for the analyses. In total, 534 (53.5%) 176 
people fulfilled these requirements: 42% (n = 226) were female and 58% (n = 308), male. The 177 
mean age was 57 years (SD = 15). Only people 18 years or older were allowed to participate 178 
in the study. The self-reported educational level ranged from lower primary school (2%, n = 179 
11), secondary school (7%, n = 37), professional school (45%, n = 244), high school (19 %, n 180 
= 103), to technical universities and universities (25%, n = 133). Fourteen participants (2%) 181 
did not report their educational level.  182 
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Questionnaire 183 
The questionnaire was designed to measure risk and benefit perceptions of gene technology 184 
applications. For all questions, six response categories were used, with the two extreme points 185 
verbally depicted (1 = no benefit/risk, 6 = high benefit/risk). Twelve applications covering 186 
medical, nutritional, agricultural, and industrial, as well as animals, plants, and 187 
microorganisms, were created based on a previous study conducted by Connor and 188 
Siegrist (2010). These items are presented in Table I and Table II. Furthermore, socio-189 
demographic characteristics such as gender, age, and level of education were recorded. 190 
Data Analysis 191 
In order to test the relationship between the repeated measures and the pattern of change over 192 
time, we applied structural equation modelling procedures (SEM). Firstly, SEM was applied 193 
to test the plausibility of the postulated correlational model. Parameters were estimated using 194 
the statistical software package AMOS 18. To calculate the SEM coefficients, the maximum 195 
likelihood method of estimation was applied. The assessment of the model fit was based on 196 
the Comparative Fit Index (CFI), the residual values, the root mean square error of 197 
approximation (RMSEA), and the meaningfulness of the model (Hu and Bentler 1995). CFI 198 
values higher than .90 represent an acceptable fit and values higher than .95, a good fit (Byrne 199 
2010). RMSEA values lower than .08 also represent an acceptable fit and values below .05, a 200 
good fit (Byrne 2010). Parameters were added in consideration of substantive meaningfulness 201 
and parsimony. The significance level for hypothesis tests was set to  = .05.  202 
The analyses were conducted in three steps. First exploratory factor analyses were 203 
performed for each latent variable to test whether the postulated measurement model was 204 
appropriate for the data from the first wave. After establishing the measurement model, the 205 
observed data of both waves were fitted to the hypothesised model. The measurements 206 
components and the structural components were combined in one model. We also correlated 207 
the error terms of both measurement times in order to achieve reliable estimates of the 208 
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regression paths (Jöreskog 1979). The error terms for the same measurement tend to correlate 209 
when investigating the same sample, which applies to this longitudinal study. For example, 210 
the measurement error of an item that belongs to the latent factor “medical applications” in 211 
2008 is related to the measurement error of the identical item in 2010. On account of 212 
simplicity, the correlations between the error terms of the indicator variables are, not shown in 213 
Figures 1 and 2. 214 
The modification indices were used to identify parameter additions that would contribute to a 215 
better-fitting model. Lastly, the invariance of all factor loadings and correlations of both 216 
models (risk and benefit) was tested across the two measurement times. 217 
Only participants who answered all questions were included for testing the model. 218 
Participants with incomplete data sets were deleted. Data analysis was based on 491 219 
participants: 42% (n = 205) were female and 58% (n = 286), male.  220 
 221 
Results 222 
Model development 223 
An exploratory factor analysis with principle components as the extraction method and 224 
oblimin rotation was used to detect the underlying structure of participants’ risk and benefit 225 
perception of the 12 biotechnology applications. Results show that people distinguish 226 
between the applications. All applications can be found in Table I (benefit) and Table II 227 
(risk). For benefit, one component includes medical applications. The second component 228 
includes food and crop applications. The third component consists of applications that include 229 
animals. The last component includes applications where different products are improved 230 
independently of the type of application or the organism involved. All groups of applications 231 
have rather high correlations between the two measurement points: r > .60 (Table III). 232 
Between 2008 and 2010, people’s benefit perception has only changed a little (Table III).  233 
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For risk, people distinguish between three different types of application. Similar to the 234 
benefit components, one component consists of the medical applications. The second 235 
component includes all food- and crop-related applications, and the third component includes 236 
all applications where animals are involved. People’s risk perception of medical applications 237 
and food and crop applications increased from 2008 to 2010 (Table III), but the effect size is 238 
very small. The correlations of perceived risks in 2008 and 2010 are substantial (.49 < r < 239 
.59), but a bit lower than the correlations for the benefit assessments.  240 
General model of benefit perception 241 
The initial model for benefit is shown in Figure 1 and represents the four factors, which are 242 
allowed to correlate with each other at both measurement times. Furthermore, Figure 1 also 243 
shows the correlations and the path coefficients. The initial model for benefit resulted in a 244 
suboptimal fit: 2 = 925.8, df = 224, CFI = .92, RMSEA = .08. However, the modification 245 
indices suggested allowing additional correlations for both years between the error terms of 246 
the observed variables V9 and V10. This seems plausible as both applications involve 247 
genetically modified animals. Furthermore, the modification indices suggested adding a 248 
correlation for both years between the error terms of V6 and V11; both applications are 249 
improvements for people with allergies. The last added correlation is between the error terms 250 
of V2 and V3 for both years; these applications involve genetically modified microorganisms. 251 
All of these added correlations seem plausible. The initial and the revised model were nested, 252 
and the difference in 2, thus, was used for calculating the improvement in fit of the new 253 
model. For the revised model, 2 has dropped significantly (2 = 266.5, df = 6, p < .001) 254 
and improved the overall fit (2 = 659.3, df = 218, CFI = .951, RMSEA = .064). The final 255 
model is presented in Figure 1. Estimates along each path represent standardised coefficients, 256 
which represent effect sizes. The structural model explains 54% of the variance in benefit 257 
perception of the improved food products. Furthermore, 48% of the variance is explained in 258 
the benefit perception of food and crop plant applications, and 53% of the variance is 259 
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explained in the benefit perception of applications involving animals. For the medical 260 
applications, 46% of the variance is explained by the structural model. 261 
General model of risk perception 262 
The initial model for risk is shown in Figure 2 and represents the three factors, which are 263 
allowed to correlate with each other at both measurement times and the path coefficients. The 264 
initial model for risk resulted in a good fit: 2 = 1004, df = 231, CFI = .93, RMSEA = .083. 265 
However, the modification indices suggested allowing additional correlations for both years 266 
between the error terms of the observed variables V2 and V3, V2 and V1, V8 and V9, and V6 267 
and V11. This seems plausible as V2 and V3 both concern genetically modified 268 
microorganisms. This is also true for V2 and V1. V8 and V9 are applications, which concern 269 
improved food products, and V6 and V11 are applications especially for people with allergies. 270 
The initial and the revised model were nested, and the difference in 2 was again used for 271 
calculating the improvement in fit of the new model. For the revised model, 2 has dropped 272 
significantly (2 = 277, df = 8, p < .001) and improved the overall fit (2 = 727.2, df = 223, 273 
CFI = .956, RMSEA = .068). The final model is presented in Figure 2. Estimates along each 274 
path represent standardised coefficients, which represent effect sizes. The structural model 275 
explains 26% of the variance in the risk perception of food and crop plant applications. 276 
Furthermore, 23% of the variance is explained in the risk perception of applications involving 277 
animals. Twenty-four percent of the variance is explained in the risk perception of medical 278 
applications.  279 
Invariance of the measurement models 280 
The invariance of the measurement model was tested by comparing the baseline model with 281 
two constrained models. In the first model, all factor loadings were constrained to be equal. In 282 
the second model, correlations between the error terms, correlations between latent variables, 283 
and measurement weights were constrained to be equal for the two measurement points. Table 284 
IV shows the results for both the risk and benefit models. For both models, results show that 285 
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constraining the factor loadings at both measurement times to be equal does not result in 286 
worsening of the overall model fit. In other words, the factor loadings are equal across the two 287 
measurement points. Whereas, additionally constraining the structural paths of the CFAs to be 288 
equal results in worsening of the overall model fit. This implies that the correlations between 289 
the factors were not equal in 2008 and 2010. 290 
Discussion 291 
Since there has recently been increased interest in involving the public in decision-making 292 
processes (Rowe and Frewer 2000), it is necessary to evaluate how stable people’s 293 
preferences towards emerging technologies are. Only when attitudes and perceptions are 294 
stable over time can governance and other policy-making agencies take preferences 295 
pronounced by the public into account (e.g. when deciding about the allowance of gene 296 
technology in food production in Europe or the ban of nuclear power). The present study is, to 297 
the best of our knowledge, the first longitudinal study assessing the stability of risk and 298 
benefit perceptions of various gene technology applications over two years.  299 
Results of the present study show that people’s risk and benefit perceptions of gene 300 
technology applications differ. When assessing the risks of gene technology applications, 301 
people take the genetically modified organism into account as well as the field of research 302 
from which the applications derive from. Confronting people directly with a set of 303 
applications where all aspects were considered (the type of application as well as the 304 
organism involved) results in participants distinguishing between medical applications, food 305 
and crop plant applications, and applications involving animals. Our results concur with 306 
results found in other studies, where people were confronted with applications involving GM 307 
microorganisms, plants, and human DNA (Connor and Siegrist 2010, 2013), as well as with 308 
studies that show a differentiation between medical and non-medical applications e.g. 309 
(Connor and Siegrist 2010; Frewer et al. 2013a). Results of the present study also show that 310 
when people evaluate the benefits of gene technology, they perceive applications that 311 
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represent an improvement of food products independent of all other applications, regardless 312 
of the type of application or the organism involved. These applications are comparable with 313 
the second-generation GM crop plants, which deliver consumer-related benefits such as the 314 
enhancement of functional properties (Hartl and Herrmann 2009). This, furthermore, indicates 315 
that people may think of themselves when evaluating benefits and therefore, perceive benefits 316 
in a more detailed way (Bredahl 1999). In contrast risks tend to affect a wide range of people 317 
and not just an individual (Fleury-Bahi 2008). Therefore, the distinction of gene technology 318 
applications on an individual level as present when evaluating the benefits is not present when 319 
evaluating the risks. Our results show that applications are perceived differently regarding 320 
risks and benefits, and are concurrent with other studies, although most of these studies do not 321 
include both dimensions: the field of application and the organism being manipulated 322 
(Frewer, Howard, and Shepherd 1997; Connor and Siegrist 2010; Frewer, Howard, and 323 
Shepherd 1995; Frewer et al. 1997; Hoban 1998; Magnusson and Hursti Koivisto 2002). 324 
By applying structural equation modelling, we show how stable risk and benefit 325 
perceptions of gene technology applications are over a period of two years. Results of the 326 
structural equation modelling suggest that the perception of risks and benefits for all groups 327 
of applications are moderately stable (r = 0.5 - 0.7) compared to high correlations (r > 0.7) 328 
found in a study on nuclear power, which has been conducted before and after the 329 
Fukushima accident (Visschers and Siegrist 2013). People’s risk perception is less stable 330 
than their benefit perception of gene technology applications. This is not surprising since the 331 
benefits are clearly stated for the applications, i.e. ‘Genetically modified micro-organisms that 332 
produce vaccines against infectious diseases.’ However, the risks are not stated and people 333 
have to imagine the associated risk themselves, which means that they either need to have the 334 
necessary knowledge to estimate the risks or they need to rely on certain cues for providing 335 
their answers. It seems likely that participants relied on the affect heuristic (Finucane et al. 336 
2000; Slovic et al. 2002) for providing their risk estimates. In other words, the affect heuristic 337 
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may have been more important for participants’ risk perceptions compared with participants’ 338 
benefit perceptions. Since data collection took place in the vicinity of the field trials with 339 
genetically modified plants another possible explanation could be that people actively 340 
looked for information and therefore gained more knowledge about risks associated 341 
with gene technology. This may have constituted to the less stable risk perception 342 
between the two measurement points. Results of the present study are also in line with 343 
Slovic’s (1995) idea that people construct their preferences when they fill in a questionnaire. 344 
This could be a plausible explanation for the low correlations observed for risk perception. 345 
Participants may have been influenced by different associations across the two measurement 346 
points and as a result the measured risk perceptions had rather low correlations.  347 
Only a few studies have directly addressed possible changes of preferences when 348 
people were confronted with exactly the same decision at two different time points. Some 349 
studies examined the test-retest reliability over a month and a year and found that between 350 
one quarter and one third of participants expressed different responses when confronted with 351 
the same choice twice (Camerer and Kunreuther 1989; Schoemaker and Hershey 1992). Other 352 
studies, which measured risk attitudes in different sessions, found small positive (r = 0.36) 353 
correlations over a one-year interval (Wehrung, Maccrimmon, and Brothers 1984). Higher 354 
correlations (r = 0.45) of risk attitudes were found in a study investigating 1000 Dutch 355 
farmers (Smidts 1997) over a one-year period. The results of laboratory experiments with a 356 
Danish population sample, where preferences for financial gains were investigated, show that 357 
the preferences were quite stable over seven-month and seventeen-month periods (Harrison et 358 
al. 2005; Andersen et al. 2008). Rather stable associations between several measurement 359 
points have been shown in a Swiss sample evaluating nuclear power before and after the 360 
Fukushima accident (Visschers and Siegrist 2013; Siegrist and Visschers 2012). It has to be 361 
noted, however, that the context within which people had to make their decisions differed 362 
between these studies and the present study. In contrast to afore mentioned studies, 363 
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participants in the present study had to evaluate biotechnology regarding perceived risks and 364 
benefits on predefined applications of which most stated the benefits. Compared with the 365 
previously mentioned studies the test-retest coefficients observed in our study correlate 366 
moderately.  367 
Benefit perceptions were more highly correlated than risk perceptions. The 368 
applications and the stated benefits did not change in the description between the two years, 369 
which allowed people to assess exactly the same application. This is slightly different for 370 
people’s risk perceptions. Our results show that people’s risk perceptions are less stable than 371 
their benefit perceptions. Several factors may have played a role resulting in less stable risk 372 
perceptions. Firstly, people had to conceptualise the risks associated with gene technology 373 
themselves and may have relied on the affect heuristic for their evaluations. Secondly, due to 374 
the start of the scientific field trials with genetically modified wheat plants in 2008 and the 375 
randomly selected sample of the surrounding area participants of the present study were 376 
consequently highly aware of the field trials and biotechnology. Additionally, at the 377 
beginning of the field trials in 2008 the high level of media coverage about gene technology 378 
and the field trials may have shaped people’s risk perceptions at that time. In 2010 however, 379 
at our second measurement time, media coverage was low. In 2010, media coverage about the 380 
field experiments was comparatively low and as a consequence people would have had to 381 
actively search for information about gene technology. It may have been difficult for people 382 
to conceptualise the same or similar risks associated with gene technology when they were 383 
not directly confronted by a perceived threat resulting in less stable risk perceptions. In 384 
addition, measurement errors and random variations, which can’t be accounted for may 385 
have constituted to the results obtained.  386 
To the best of our knowledge, there are no comparable studies that have examined the 387 
stability of technological risks or environmental hazards perceptions over a period of two 388 
years. The question is, therefore, whether the results found for gene technology can be 389 
 16 
generalized to other technologies. Since gene technology as a tool of biotechnology is not a 390 
novel technology, but rather a constantly developing technology with new tools emerging 391 
especially in areas of gene sequencing techniques (Mardis 2011). People seem to have 392 
relatively stable benefit perceptions of the applications but less stable risk perceptions. Owing 393 
to the results obtained in the present study, one could expect that for common, recognised, 394 
or well-established technologies, people’s perceptions are quite stable (e.g. nuclear power). 395 
People are to a certain extent familiar with such technologies and have been able to form an 396 
opinion over time. Nonetheless, for novel and emerging technologies (e.g. nanotechnology), 397 
people’s perceptions can change with new implications or developments. It seems plausible, 398 
therefore, that risk and benefit perception of nanotechnology, for example, are less stable 399 
compared to perceptions of gene technology. On a continuum from well established and 400 
entrenched technologies to novel and emerging technologies we expect gene technology 401 
to lay somewhere in between depending on the type of technological tool which is 402 
represented. In general gene technology encompasses both, dimensions of entrenchment 403 
and establishment but also dimensions of novelty and development we therefore do not 404 
expect as stable perceptions as for nuclear power but more stable perceptions than we 405 
would expect for nanotechnology. In the case of novel technologies e.g. nanotechnology, or 406 
new environmental hazards, it is rather likely that people construct their preferences when 407 
responding to questionnaires (Slovic 1995), and that irrelevant information could strongly 408 
bias these constructions. When people lack knowledge about such novel hazards and do not 409 
yet know which dimensions to use when evaluating these novel hazards, they may presume 410 
dangers when being asked about possible risks, which could in turn influence their 411 
perceptions.  412 
In order to inform policy makers about the developments and dynamics of 413 
people’s perceptions and preferences future research should, regularly examine people’s 414 
risk perceptions not only for novel technologies but also for constantly developing 415 
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technologies, which are often tools of well-known and established technologies. It is 416 
important that in the future research not only repeated cross-sectional designs are used, 417 
but that panel designs are used to examine changes in people’s risk perceptions of 418 
various technologies. 419 
 420 
421 
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